Presentation on Beximco Pharmaceuticals Name of the presenters ~ Faisal Bin Kamal 2009-3-10-057 2010-1-10-145 2010-1-10-149 2010-1-40-052 ~ Quazi Aritra Reyan ~ Md. Nayeem Hossain ~ Tahrim Shahriar Background of the Company Beximco Pharmaceuticals (BPL) is a leading edge pharmaceutical company based in Dhaka‚ Bangladesh. BPL started its operation in 1980 and now have grown to become nation’s one of the leading pharmaceutical companies. ~ BPL supplies more than 10% of country’s
Premium Pharmaceutical industry Tax Balance sheet
Introduction In 1973‚ the UK based multinational pharmaceutical company‚ ICI plc. Established a subsidiary in Dhaka‚ known as ICI Bangladesh Manufacturers Limited. In 1992‚ ICI plc. divested its share to local management‚ and the company was renamed Advanced Chemical Industries (ACI) Limited. ACI formulates and markets a comprehensive range of more than 387 products covering all major therapeutic areas‚ which come in tablet‚ capsule‚ powder‚ liquid‚ cream‚ ointment‚ gel ‚ophthalmic and injection
Premium ISO 9000 Quality management Quality assurance
Teva Pharmaceutical Industries‚ Ltd 1) External Environment: The Pharmaceutical Industry is dependent on political and legal conditions of general environment. In pharmaceutical industry we have two kind of medications which are generic or innovative. Innovative pharmaceutical industry success depends on the patent protection in the industry. For example‚ in United States innovative industry can have 10 to 12 years of patent protection life from the time that product is for sale in the
Premium Generic drug Pharmaceutical industry Food and Drug Administration
OVERVIEW – INDIAN PHARMACEUTICALINDUSTRY | | 1.1 | Current Scenario | 6 | 1.2 | Major Pharmaceutical Companies | 10 | 1.3 | Government Initiatives | 12 | 1.4 | Oncology Segment | 15 | | LUNG CANCER | | 2.1 | World Scenario | 21 | 2.2 | Indian Scenario | 22 | 2.3 | About Lung Cancer | 30 | 2.4 | Stages of Lung Cancer | 36 | 2.5 | Causes of Lung Cancer | 46 | | LONG LIFE PHARMACEUTICALS PVT. LTD. | | 3.1 | Vision and Mission | 48 | 3.2 | Board of Directors | 49 | 3.3
Premium Cancer Lung cancer Oncology
Safety Implementations Table of Contents 1 Abstract 4 2 Introduction 5 3 Safe Drug Development Process in Pharmaceutical Companies 6 4 Pharmaceutical Unit Operation Safety Measures 10 4.1 Weighing and dispensing 10 4.2 Charging and discharging 10 4.3 Liquid separations 10 4.4 Filtration 11 4.5 Compounding 11 4.6 Drying 11 5 Biosafety Levels 12 5.1 Level 1 12 5.2 Level 2 12 5.3 Level 3 12 5.4 Level 4 13 6 Personal Protective Equipment 13 6.1 What is PPE? 13 6.2 OSHA Standards
Premium Occupational safety and health Personal protective equipment Pharmaceutical industry
The Case: Lorex Pharmaceuticals has come up with a new product‚ Litanol. This medicine seems to have a high potential which is developed for the treatment of high blood pressure. Company has come up with a manufacturing line and production is supposed to be begin next Monday. Following points are considered while analyzing the case: 1. The marketing team has decided to sell Litanol in sealed 10-ounce bottles‚ packaged in cases of 12 bottles each with a wholesale price of $186 per case. 2. The
Premium Standard deviation Hypertension Mac OS X
cardiovascular disorders‚ antibiotics such as Cefzil‚ antidiabetics such as Glucophage‚ and the anti-clotting medication‚ Plavix. To continue to focus on pharmaceuticals‚ in the early years of 2000-2002‚ the company divested many of their non-pharmaceutical divisions‚ such as Clairol and the Mead-Johnson Nutritional division‚ and purchased DuPont Pharmaceuticals as well as an almost 20% share of ImClone Systems‚ which was getting ready to release a new anti-cancer drug‚ Erbitux (SEC eyes Bristol-Myers‚ 2002)
Premium Revenue Marketing Inventory
There is a lot of discussion about pharmaceutical companies‚ intellectual property‚ and the global AIDS epidemic. Do pharmaceutical companies have a responsibility to distribute drugs for free or low cost in developing countries? Why is intellectual property such a big deal? What impact would South Africa’s decision to levy duties on drugs in the country have on the international distribution of drugs? Was the change that provided patent protection for pharmaceutical companies an appropriate change
Premium Generic drug Developing country Developed country
Centralized vs. Decentralized Misablaci Pharmaceutical can perform as a centralized or a decentralized organization. Many factors will determine whether Misablaci Pharmaceutical will employ centralized or decentralized operations. Since Misablaci Pharmaceutical is a large organization extending out globally both centralized and decentralized can be utilize. The company will perform in the centralized mode more effectively in the global operations. In centralization limited authority is given
Premium Management Organization Strategic management
I. TITLE “Generoso Pharmaceuticals & Chemicals‚ Inc.” II. POINT OF VIEW David Generoso‚ President (GPC)‚ a salesman III. BACKGROUND David Generoso could feel his “five-year itch” once more. He already had behind him 15 years of experience in the pharmaceutical industry and was managing an interesting portfolio of businesses revolving around pharmaceutical and chemical products. Still‚ he felt he had not exhausted the opportunities had to offer. David began his career in the Philippine
Premium